Erythropoietin: Effects on life expectancy in patients with cancer-related anaemia

Current Medical Research and Opinion, Supplement

Volumn 22, Issue 4, 2006, Pages

  Aapro, Matti ^a   Vaupel, Peter ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anaemia; Cancer; Erythropoietin; Hypoxia; Survival; Tumour progression

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOXEMIA; LIFE EXPECTANCY; LUNG CANCER; META ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OXYGEN AFFINITY; PELVIS CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW;

EID: 33845995467     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X159579     Document Type: Review

References (58)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
3. Facquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-94
4. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23
5. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(3 Suppl 7):43-6
6. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
7. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94
8. Boogaerts M, Coiffier B, Kainz C; Epoetin β QOL Working Group. Impact of epoetin β on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-95
9. Hedenus M, Adriansson M, San Miguel J, et al; Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
10. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26
11. Caro JJ, Salas M, Ward A, Goss G. Anaemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-21
12. MacRae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002;64:37-40
13. Van Belle S J-P, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11
14. Boogaerts M, Mittelman M, Vaupel P. Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models. Oncology 2005;69(Suppl 2):22-30
15. Vaupel P, Mayer A, Briest S, Höckel M. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003;63:7634-7
16. Vaupel P, Dunst J, Engert A, et al. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 2005;28:216-21
17. Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71
18. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(Suppl 5):4-9
19. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-31
20. Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-66
21. Rizzo JD, Lichtin AE, Woolf SH, et al; American Society of Clinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107
22. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
23. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76
24. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl 5):10-17
25. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist, 6th edn. Philadelphia, Baltimore, New York, London: Lippincott Williams & Wilkins, 2006
26. Teicher BA, Holden SA, Al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990;50:3339-44
27. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68
28. Höckel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15
29. Antonadou D, Cardamakis E, Puglisi M, et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur J Cancer 2001;37(Suppl 6):A530
30. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-15
31. Vansteenkiste J, Pirker R, Massuti B, et al; Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
32. Rades D, Tribius S, Yekebas EF, et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat Oncol Biol Phys 2006;65:459-65
33. Blohmer J-U, Würschmidt F, Petry U, et al. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO-and NOGGO-intergroup study. Ann Oncol 2004;15(Suppl 3):128 [abstract 477PD]
34. Machtay M, Pajak T, Suntharalingam M, et al. Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 2004;60(Suppl 1):S132
35. Untch M, Jackisch C, Lenhard MS, et al. Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC). J Clin Oncol 2005;23(Suppl 16):31 [abstract 613]
36. Österborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005;129:206-9
37. Strauss H, Haensgen G, Dunst J, et al. Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy. J Clin Oncol 2005;23(Suppl 16):484s [abstract 5121]
38. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
39. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
40. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98
41. Kelleher DK, Matthiensen U, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-34
42. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumour immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-6
43. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-61
44. Stüben G, Pöttgen C, Knühmann K, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-62
45. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60
46. Blumberg N, Heal JM. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80-1; author reply 81-2. Comment on: Lancet 2003;362:1255-60
47. Friedlin B, Korn EL. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:81; author reply 81-2. Comment on: Lancet 2003;362:1255-60
48. Haddad R, Posner M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:79-80; author reply 81-2. Comment on: Lancet 2003;362:1255-60
49. Kaanders JH, van der Kogel AJ. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:78-9; author reply 81-2. Comment on: Lancet 2003;362:1255-60
50. Leyland-Jones B, Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80; author reply 81-2. Comment on: Lancet 2003;362:1255-60
51. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol 2006;3:152-64
52. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
53. Glaspy J, Dunst J. Can erythropoietin therapy improve survival? Oncology 2004;67(Suppl 1):5-11
54. Coiffier B, Boogaerts M, Aapro M, et al. Thromboembolic events in patients with cancer treated with epoetin beta: a meta-analysis of controlled clinical trials. Ann Oncol 2004;15 (Suppl 3):iii221 [abstract 840P]
55. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-8
56. Aapro M, Dunst J, Morere JF, et al. Effects of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 2004;15 (Suppl 3):iii222 [abstract 841-P]
57. Leonard RC, Aapro M, Chan S, et al. Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy. Ann Oncol 2004;15 (Suppl 3):iii50 [abstract 188P]
58. Marangolo M, Lang I, Beato C, et al. Breast cancer - Anaemia and the Value of Erythropoietin (BRAVE): preliminary results from a study of the efficacy of epoetin beta 30,000IU once weekly in patients with metastatic breast cancer receiving chemotherapy. Eur J Cancer 2005;3(Suppl):388 [abstract 1347]